Since completing the BIT225-009 Phase 2 HIV-1 clinical trial and releasing positive results in late 2018, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225. This has involved detailed post-trial analyses of trial samples. These analyses now provide key information on how BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI.
With this happening overnight ... being out of this stock is a big risk.
- Forums
- ASX - By Stock
- BIT
- Holy Grail
Holy Grail, page-19
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.002(10.5%) |
Mkt cap ! $18.94M |
Open | High | Low | Value | Volume |
2.0¢ | 2.1¢ | 2.0¢ | $11.58K | 578.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 60000 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 659880 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 60000 | 0.020 |
12 | 2363963 | 0.019 |
10 | 1719636 | 0.018 |
9 | 2358408 | 0.017 |
12 | 1659350 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 659880 | 4 |
0.022 | 997769 | 4 |
0.023 | 1299422 | 3 |
0.024 | 112849 | 1 |
0.025 | 223000 | 3 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online